文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症儿科与产科急症

儿童脓毒症相关急性肾损伤亚表型的外部验证、分子特征与治疗相关性

External Validation, Molecular Signatures, and Therapeutic Relevance of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes.
PubMed 文献 · Crit Care Med · 2026-03-30
一句话结论儿童脓毒症相关急性肾损伤可分为pSAKI-1和pSAKI-2两个亚表型,pSAKI-2预后更差,且两亚表型对糖皮质激素和血管加压素的治疗反应可能存在差异。

该研究为一项正在进行的多中心前瞻性观察性研究的二次分析,纳入美国10个PICU中1周至18岁、发生早期(第1-2天)脓毒症相关急性肾损伤(SAKI)的儿童871例。结果显示,665例(76%)为pSAKI-1亚表型,206例(24%)为pSAKI-2亚表型;pSAKI-2患者病情更重,第7天严重急性肾损伤(aOR 3.2;95%CI 2.1-4.7;p<0.001)和死亡(aOR 2.7;95%CI 1.6-4.4;p<0.001)风险独立更高,无PICU天数和无血管活性药物天数更少(p<0.001)。pSAKI-2的生物学标志物特征为炎症、内皮功能障碍和高肾素血症更显著。倾向性评分匹配分析中,pSAKI-1患者接受糖皮质激素后第7天严重急性肾损伤更多(28% vs. 19%,p=0.023)、无PICU天数少2天(p=0.04)、死亡率更高(10% vs. 3.7%,p=0.008),pSAKI-2患者中未观察到差异;血管加压素在倾向性评分匹配分析中未发现异质性治疗效应,但逆概率治疗加权分析显示亚表型、血管加压素与无血管活性药物天数之间存在显著交互作用(p=0.003)。

要点

  • 在871例早期儿童SAKI患者中,pSAKI-2亚表型占24%,其第7天严重急性肾损伤风险独立更高(aOR 3.2;95%CI 2.1-4.7;p<0.001)。
  • pSAKI-2患者死亡风险独立更高(aOR 2.7;95%CI 1.6-4.4;p<0.001),无PICU天数和无血管活性药物天数更少(p<0.001)。
  • pSAKI-2的生物学标志物特征为炎症、内皮功能障碍和高肾素血症更显著。
  • 倾向性评分匹配分析中,pSAKI-1患者接受糖皮质激素后第7天严重急性肾损伤更多(28% vs. 19%,p=0.023)、死亡率更高(10% vs. 3.7%,p=0.008),pSAKI-2患者中无差异。
  • 逆概率治疗加权分析显示亚表型、血管加压素与无血管活性药物天数之间存在显著交互作用(p=0.003)。

适用人群与场景

  • 美国10个PICU中1周至18岁、发生早期(第1-2天)脓毒症相关急性肾损伤(SAKI)的儿童。

研究设计与关键结果

  • 研究类型为正在进行的多中心前瞻性观察性研究的二次分析,纳入美国10个PICU中1周至18岁、早期(第1-2天)SAKI儿童871例,无干预。
  • 665例(76%)为pSAKI-1亚表型,206例(24%)为pSAKI-2亚表型;第1-2天时pSAKI-2患者病情更重,包括急性肾损伤分期更高、血管活性药物负担更大、血小板计数更低、乳酸值和国际标准化比值更高。
  • pSAKI-2患者第7天严重急性肾损伤风险独立更高(aOR 3.2;95%CI 2.1-4.7;p<0.001),死亡风险独立更高(aOR 2.7;95%CI 1.6-4.4;p<0.001),无PICU天数和无血管活性药物天数更少(p<0.001)。
  • pSAKI-2的生物学标志物特征为炎症、内皮功能障碍和高肾素血症更显著。
  • 倾向性评分匹配分析中,pSAKI-1患者接受糖皮质激素后第7天严重急性肾损伤更多(28% vs. 19%,p=0.023)、无PICU天数少2天(p=0.04)、死亡率更高(10% vs. 3.7%,p=0.008);pSAKI-2患者中未观察到差异。
  • 倾向性评分匹配分析未发现血管加压素的异质性治疗效应;逆概率治疗加权分析显示亚表型、血管加压素与无血管活性药物天数之间存在显著交互作用(p=0.003)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察性研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,基于 readily available 数据得出的pSAKI亚表型具有独特的生物学标志物特征和差异治疗反应,代表了一种床旁富集的潜在机制。
  • 倾向性评分匹配分析中,pSAKI-1患者接受糖皮质激素后第7天严重急性肾损伤更多(28% vs. 19%,p=0.023)、死亡率更高(10% vs. 3.7%,p=0.008),pSAKI-2患者中未观察到差异。
  • 逆概率治疗加权分析显示亚表型、血管加压素与无血管活性药物天数之间存在显著交互作用(p=0.003)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Sepsis-associated acute kidney injury (SAKI) is a heterogeneous condition that lacks disease-modifying treatments, and precision medicine approaches are needed. We previously derived two reproducible pediatric SAKI subphenotypes (pSAKI-1 and pSAKI-2) from readily available clinical data. We aimed to externally validate the prognostic relevance of these subphenotypes, evaluate their molecular signatures, and assess for heterogeneity of treatment effect (HTE) across subphenotypes with sepsis therapies.

DESIGN: Secondary analysis of an ongoing multicenter, prospective, observational study of children.

SETTING: Ten PICUs in the United States from January 2002 to February 2025.

PATIENTS: Patients 1 week to 18 years old with early (day 1-2) SAKI.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Among 871 patients, 665 (76%) were assigned pSAKI-1 and 206 (24%) to pSAKI-2. On day 1-2, the pSAKI-2 cohort had greater severity of illness, including higher acute kidney injury stage and vasoactive burden, lower platelet counts, and higher lactate values and International Normalized Ratios. These pSAKI-2 patients also had uniformly worse outcomes, including independently higher odds of day 7 severe acute kidney injury (adjusted odds ratio [aOR] 3.2; 95% CI, 2.1-4.7; p < 0.001), death (aOR 2.7; 95% CI, 1.6-4.4; p < 0.001), and fewer PICU-free and vasoactive-free days ( p < 0.001). The biomarker signature of pSAKI-2 was characterized by greater inflammation, endothelial dysfunction, and hyperreninemia. On propensity score matched (PSM) analysis, pSAKI-1 patients who received corticosteroids had more day 7 severe acute kidney injury (28% vs. 19%, p = 0.023), 2 fewer PICU-free days ( p = 0.04) and greater mortality (10% vs. 3.7%, p = 0.008); no differences were seen in pSAKI-2 patients. Although no HTE was identified on PSM analysis for vasopressin, inverse probability treatment weighting analysis demonstrated a significant interaction between subphenotype-, vasopressin- and vasoactive-free days ( p = 0.003).

CONCLUSIONS: We externally validated the prognostic relevance of two pSAKI subphenotypes derived from readily available data. These subphenotypes have unique biomarker signatures and differential responses to treatment, representing a potential mechanism for bedside enrichment.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Stanski NL, Zhang B, Ouyang J, et al. External Validation, Molecular Signatures, and Therapeutic Relevance of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes. Crit Care Med. 2026. PMID: 42159375. doi:10.1097/CCM.0000000000007135

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。